安科生物：获CD7-CAR-T细胞药物全国独家商业化权益

Core Insights - Anke Bio announced a strategic partnership with Boshengji Pharmaceutical Technology (Suzhou) Co., Ltd. to promote the sales of the PA3-17 injection product, which is a CAR-T cell therapy targeting CD7 [1] - The PA3-17 injection is the first globally approved CAR-T cell therapy for clinical trials targeting CD7, aimed at treating adult relapsed and refractory CD7-positive hematologic malignancies [1] - The product has been included in the list of breakthrough therapies by the National Medical Products Administration (NMPA) and is currently in a critical Phase II clinical trial [1] Summary by Sections - Strategic Partnership: Anke Bio and Boshengji have signed a framework agreement for exclusive agency rights for the PA3-17 injection in Greater China, with a formal agreement to follow after the product's market application submission [1] - Product Details: PA3-17 injection is developed by Boshengji's subsidiary and is the first of its kind to receive clinical trial approval, focusing on a significant medical need in hematologic cancers [1] - Future Collaboration: Boshengji has committed to prioritizing Anke Bio as the exclusive agency for future product launches, ensuring a long-term collaboration for sales and promotion in the region [1]